How O’Heeron was paid
$1.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Other | Total |
|---|---|---|---|---|
| Pete O’HeeronChairperson and CEO | $617,500 | $408,827 | $39,864 | $1,066,191 |
| Hamid Khoja, Ph.D.Chief Scientific Officer | $425,000 | $170,560 | $58,510 | $654,070 |
| Ruben A. GarciaGeneral Counsel | $425,000 | $170,560 | $31,240 | $626,800 |
What changed and why
- $1.1M$1,066,191 CEO total compensation in 2025 fell from $1,805,199 in 2024.
- $409K$408,827 of CEO compensation was option-award grant-date fair value.
- No named executive officer received a bonus payment for 2025 performance.
- 55%55% of CEO base salary was the target annual cash bonus.
- 2025 performance objectives covered clinical trials, regulatory filings, capital raising, and spending management.
- The Compensation Committee engaged Anderson Pay Advisors for competitive compensation and equity guidance.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.